Journal
CLINICAL EPIGENETICS
Volume 8, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/s13148-016-0223-4
Keywords
Methylome; Lysine methylation; Histone methyltransferase; Histone demethylase; Clinical trial; Methyltransferase inhibitors; Demethylase inhibitors; Epigenetics; Histone modifications
Categories
Funding
- Deutsche Forschungsgemeinschaft (DFG) [SFB992, SPP1463]
- COST action EPICHEMBIO [CM1406]
Ask authors/readers for more resources
The term epigenetics is defined as heritable changes in gene expression that are not due to alterations of the DNA sequence. In the last years, it has become more and more evident that dysregulated epigenetic regulatory processes have a central role in cancer onset and progression. In contrast to DNA mutations, epigenetic modifications are reversible and, hence, suitable for pharmacological interventions. Reversible histone methylation is an important process within epigenetic regulation, and the investigation of its role in cancer has led to the identification of lysine methyltransferases and demethylases as promising targets for new anticancer drugs. In this review, we describe those enzymes and their inhibitors that have already reached the first stages of clinical trials in cancer therapy, namely the histone methyltransferases DOT1L and EZH2 as well as the demethylase LSD1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available